Trans-Atlantic Free Trade Agreement (TAFTA)
Formally titled: Trans-Atlantic Trade and Investment Partnership (TTIP)
The US and EU hold the world’s largest bilateral economic partnership. As recognized by the OECD, this alignment of economic power is seen by industry and government representatives as an opportunity to set what they consider a “gold standard” for IP rules which, over time, developing countries will most likely be pressed to adopt.
Consumers should not be excluded from secretive negotiations that can compromise access to health, cultural participation, and free expression. Because the inclusion of IP in TAFTA would likely result in political compromises that fail to adequately account for consumer interests, 45 civil society organizations from the US and EU have signed a Civil Society Declaration asking negotiators to keep IP Out of TTIP.
LEAKED!: "Restricted"European Commission Recommendation for a Council Decision authorisingthe opening of negotiations on a comprehensive trade and investmentagreement, called the Transatlantic Trade and Investment Partnership,between the European Union and the United States of America
Public Citizen Resources
Blog post on TAFTA: First SOPA then ACTA, now TAFTA- here we go again
See Civil Society Declaration asking negotiators to keep IP Out of TAFTA.
See Presentation "IP Out of TAFTA" by Dr. Burcu Kilic, Global Access to Medicines Program
See Presentation "Confidential Commercial Information vs. Our Right to Know" by Peter Maybarduk, Global Access to Medicines Program
February 18, 2016 - Public Citizen, Health Action International & Commons Network Position Statement on TTIP and Access to Medicines -- Available in Spanish here
December 18, 2014 - Coalition Statement: EU trade secrets directive threat to health, enviroment, free speech and worker mobility (updated March 20, 2015)
EU-letter to US on handling of documents (explaining EU secrecy practices)
10 Reasons Why Intellectual Property (IP) Should BeKept Out of the Trans-Atlantic Free Trade Agreement (TAFTA or T-TIP)
- The European Parliament voted overwhelmingly against the ACTA in 2012.
- Making genes patentable would raise the cost of diagnostic tests and cancer research.
- Making medical procedures patentable would raise the cost of healthcare services.
- Harmonizing regulatory exclusivity could result in longer pharmaceutical monopolies.
- Linking pharmaceutical patents to regulatory approval would impede generic competition.
- Imposing indirect infringement liability on ISPs would significantly raise the costs of providing internet services that facilitate freedom of speech and access to information.
- Strict compliance with the copyright three-step test would raise costs for consumers.
- Protecting facts in databases would inhibit access to knowledge.
- Requiring libraries to pay lending royalties would inhibit access to culture and knowledge.
- Harmonizing approaches to geographical indications (GIs) would be near impossible.
For a pdf version of this list with linked sources: 10 Reasons why IP should not be included in TAFTA
Back to Access to Medicines Page